The antiangiogenic effect of CBT-143-S-F6F7 was demonstrated in IHC analysis of a subcutaneous HCC tumor, and CBT-143-S-F6F7 reduced the number of vascular endothelial cells (CD31+ cells), leading to decreased angiogenesis and nutrient supply and tumor growth inhibition. Here, PECAM1 is linked to neoplasm.